Literature DB >> 25381586

MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line.

W Ziyan1, L Yang2.   

Abstract

BACKGROUND: Recent studies have shown that microRNA-21 (miR-21) is overexpressed in solid tumors and implicated in the modulation of drug-induced resistance.
METHODS: In this study, we investigated the anti-tumor effects of miR-21 on the sensitivity of osteosarcoma cells to CDDP.
RESULTS: Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP. Osteosarcoma cells transfected with miR-21 mimics were significantly resistant to CDDP, while suppression of miR-21 in osteosarcoma cells led to enhanced CDDP cytotoxicity. Moreover, the miR-21-induced changes in chemoresponse were ameliorated by down-regulation of bcl-2 by its siRNA.
CONCLUSION: The miR-21 in osteosarcoma cells is a significant modulator of the anti-tumor effect of CDDP by regulating the expression of bcl-2, and the study reveals a novel mechanism of osteosarcoma drug resistance.

Entities:  

Keywords:  Cisplatin; Drug resistance; MicroRNA-21; Osteosarcoma

Mesh:

Substances:

Year:  2014        PMID: 25381586     DOI: 10.1007/s11845-014-1225-x

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  30 in total

1.  MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

Authors:  Elisa Giovannetti; Niccola Funel; Godefridus J Peters; Marco Del Chiaro; Leyla A Erozenci; Enrico Vasile; Leticia G Leon; Luca E Pollina; Annemieke Groen; Alfredo Falcone; Romano Danesi; Daniela Campani; Henk M Verheul; Ugo Boggi
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

2.  MicroRNAs modulate hematopoietic lineage differentiation.

Authors:  Chang-Zheng Chen; Ling Li; Harvey F Lodish; David P Bartel
Journal:  Science       Date:  2003-12-04       Impact factor: 47.728

Review 3.  Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)--advantages, disadvantages, and controversial issues.

Authors:  N Jaffe
Journal:  Cancer Treat Res       Date:  1993

4.  Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance.

Authors:  Ying Huang; Pascale Anderle; Kimberly J Bussey; Catalin Barbacioru; Uma Shankavaram; Zunyan Dai; William C Reinhold; Audrey Papp; John N Weinstein; Wolfgang Sadée
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

5.  Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells.

Authors:  Lilly Y W Bourguignon; Christina C Spevak; Gabriel Wong; Weiliang Xia; Eli Gilad
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

Review 6.  New molecular insights into osteosarcoma targeted therapy.

Authors:  Jilong Yang; Wei Zhang
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

7.  MicroRNAs modulate the chemosensitivity of tumor cells.

Authors:  Paul E Blower; Ji-Hyun Chung; Joseph S Verducci; Shili Lin; Jong-Kook Park; Zunyan Dai; Chang-Gong Liu; Thomas D Schmittgen; William C Reinhold; Carlo M Croce; John N Weinstein; Wolfgang Sadee
Journal:  Mol Cancer Ther       Date:  2008-01-09       Impact factor: 6.261

8.  MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.

Authors:  Shoumei Bai; Mohd W Nasser; Bo Wang; Shu-Hao Hsu; Jharna Datta; Huban Kutay; Arti Yadav; Gerard Nuovo; Pawan Kumar; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

9.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

Review 10.  Molecular mechanisms of drug resistance in acute myeloid leukaemia.

Authors:  Donal P McLornan; Mary Frances McMullin; Patrick Johnston; Daniel B Longley
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-06       Impact factor: 4.481

View more
  19 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

3.  Inhibition of miRNA-21 attenuates the proliferation and metastasis of human osteosarcoma by upregulating PTEN.

Authors:  Chen Li; Binwu Xu; Xinxin Miu; Zhongbo Deng; Hang Liao; Liang Hao
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

4.  Exosome-mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR-21.

Authors:  Changwen Jing; Haixia Cao; Xiaobing Qin; Shaorong Yu; Jianzhong Wu; Zhuo Wang; Rong Ma; Jifeng Feng
Journal:  Oncol Lett       Date:  2018-04-27       Impact factor: 2.967

5.  MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma.

Authors:  K Tian; R Di; L Wang
Journal:  Cancer Gene Ther       Date:  2015-07-10       Impact factor: 5.987

6.  Long non-coding RNA CASC2 enhanced cisplatin-induced viability inhibition of non-small cell lung cancer cells by regulating the PTEN/PI3K/Akt pathway through down-regulation of miR-18a and miR-21.

Authors:  Li Li; Haifeng Zhang; Xiaolong Wang; Jiali Wang; Haitao Wei
Journal:  RSC Adv       Date:  2018-04-30       Impact factor: 4.036

Review 7.  PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.

Authors:  Palanisamy Nallasamy; Srinivas Chava; Sumit S Verma; Shruti Mishra; Santhi Gorantla; Don W Coulter; Siddappa N Byrareddy; Surinder K Batra; Subash C Gupta; Kishore B Challagundla
Journal:  Semin Cancer Biol       Date:  2017-11-28       Impact factor: 15.707

8.  MicroRNA-765 Enhances the Anti-Angiogenic Effect of CDDP via APE1 in Osteosarcoma.

Authors:  Wei Liang; Xi Wei; Qing Li; Nan Dai; Chong-Yi Li; Yi Deng; Xuan Jiang; Xiao-Rong Tan; Xiao-Yan Dai; Meng-Xia Li; Cheng-Xiong Xu; Dong Wang; Zhao-Yang Zhong
Journal:  J Cancer       Date:  2017-06-02       Impact factor: 4.207

9.  MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells.

Authors:  Vanita Vanas; Barbara Haigl; Verena Stockhammer; Hedwig Sutterlüty-Fall
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

10.  Research Progress of MicroRNA in Chemotherapy Resistance of Osteosarcoma.

Authors:  Zhaopeng Tang; Yubao Lu; Yutong Chen; Jiarui Zhang; Zhijun Chen; Qianfeng Wang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.